Novavax vaccine meets mid-stage trial goal, shares rise

(Reuters) – Novavax Inc said its vaccine to treat a virus that causes respiratory tract infections met the main goal, of immunizing women of childbearing age, in a mid-stage trial. The company’s shares were up 8.5 percent at $2.35 in extended trading. The vaccine against respiratory syncytial virus (RSV) could induce immune responses at levels that can protect infants through a transfer of antibodies from the mother, Novavax said citing trial data. The vaccine was well-tolerated, with a safety profile similar to its early-stage trial. …